$PALI
PALISADE BIO, INC.

2024 Q3 Form 10-Q Financial Statement

#000095017024095432 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.456M $1.583M
YoY Change -12.81% 10.54%
% of Gross Profit
Research & Development $16.00M $2.628M
YoY Change 818.48% 20.72%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K
YoY Change -50.0%
% of Gross Profit
Operating Expenses $3.593M $4.211M
YoY Change -4.9% 16.68%
Operating Profit -$3.593M -$4.211M
YoY Change -4.9% 16.68%
Interest Expense $6.000K $2.000K
YoY Change -25.0% -33.33%
% of Operating Profit
Other Income/Expense, Net $106.0K $131.0K
YoY Change -41.76% -39.35%
Pretax Income -$3.487M -$4.080M
YoY Change -3.14% 20.25%
Income Tax
% Of Pretax Income
Net Earnings -$3.487M -$4.080M
YoY Change -3.03% 20.25%
Net Earnings / Revenue
Basic Earnings Per Share -$2.32 -$3.32
Diluted Earnings Per Share -$2.32 -$3.32
COMMON SHARES
Basic Shares Outstanding 1.184M 937.6K
Diluted Shares Outstanding 1.500M 1.228M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.040M $11.35M
YoY Change -47.49% -30.79%
Cash & Equivalents $8.000M $11.40M
Short-Term Investments
Other Short-Term Assets $734.0K $831.0K
YoY Change -10.49% -14.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.870M $12.31M
YoY Change -45.47% -29.29%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000K $4.000K
YoY Change -70.0% -63.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $324.0K $387.0K
YoY Change -40.11% -34.63%
Total Long-Term Assets $466.0K $559.0K
YoY Change -41.82% -36.41%
TOTAL ASSETS
Total Short-Term Assets $8.870M $12.31M
Total Long-Term Assets $466.0K $559.0K
Total Assets $9.336M $12.87M
YoY Change -45.3% -29.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $366.0K $514.0K
YoY Change -61.47% -44.25%
Accrued Expenses $1.509M $1.555M
YoY Change 90.05% 160.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $235.0K $349.0K
YoY Change -9.62% -15.09%
Total Short-Term Liabilities $2.681M $2.836M
YoY Change 1.21% 21.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $47.00K $86.00K
YoY Change -86.18% -44.52%
Total Long-Term Liabilities $47.00K $86.00K
YoY Change -86.18% -44.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.681M $2.836M
Total Long-Term Liabilities $47.00K $86.00K
Total Liabilities $2.728M $2.922M
YoY Change -8.61% 17.35%
SHAREHOLDERS EQUITY
Retained Earnings $132.6M -$129.1M
YoY Change 11.9% -212.36%
Common Stock $11.00K $9.000K
YoY Change -88.04% -86.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.608M $9.949M
YoY Change
Total Liabilities & Shareholders Equity $9.336M $12.87M
YoY Change -45.3% -29.63%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.487M -$4.080M
YoY Change -3.03% 20.25%
Depreciation, Depletion And Amortization $1.000K $1.000K
YoY Change -50.0%
Cash From Operating Activities -$3.133M -$3.499M
YoY Change 17.78% 59.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -180.0K 3.576M
YoY Change -111.46% -32.64%
NET CHANGE
Cash From Operating Activities -3.133M -3.499M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -180.0K 3.576M
Net Change In Cash -3.313M 77.00K
YoY Change 203.94% -97.52%
FREE CASH FLOW
Cash From Operating Activities -$3.133M -$3.499M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.133M -$3.499M
YoY Change 17.78% 58.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1184487
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11353000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12432000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
959000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
12312000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13328000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
387000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q2 us-gaap Assets
Assets
12871000
CY2023Q4 us-gaap Assets
Assets
14052000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
514000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
698000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1555000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
288000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
778000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121000
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
349000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
158000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2836000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2586000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
60000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000
CY2024Q2 us-gaap Liabilities
Liabilities
2922000
CY2023Q4 us-gaap Liabilities
Liabilities
2739000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
966345
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
966345
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618056
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618056
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139051000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132811000
CY2024Q2 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-129113000
CY2023Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-121506000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9949000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12871000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14052000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2628000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2177000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4842000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3418000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1583000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1432000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3042000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2970000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
4211000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3609000
us-gaap Operating Expenses
OperatingExpenses
7884000
us-gaap Operating Expenses
OperatingExpenses
6388000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4211000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3609000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7884000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6138000
CY2024Q2 us-gaap Interest Expense
InterestExpense
2000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
3000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
133000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
219000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
280000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
408000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
131000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
216000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
277000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
405000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4080000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3393000
us-gaap Net Income Loss
NetIncomeLoss
-7607000
us-gaap Net Income Loss
NetIncomeLoss
-5733000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1228453
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1228453
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
427862
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
427862
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1000367
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1000367
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
357572
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
357572
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.32
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.32
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.93
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.03
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10064000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4080000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362000
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
73000
CY2024Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-25000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9949000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13747000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3393000
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
144000
CY2023Q2 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15800000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
us-gaap Net Income Loss
NetIncomeLoss
-7607000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
480000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
73000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-25000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9949000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
us-gaap Net Income Loss
NetIncomeLoss
-5733000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
237000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1350000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15800000
us-gaap Net Income Loss
NetIncomeLoss
-7607000
us-gaap Net Income Loss
NetIncomeLoss
-5733000
us-gaap Depreciation
Depreciation
2000
us-gaap Depreciation
Depreciation
3000
pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
56000
pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
50000
pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
-5000
pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
59000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
73000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Share Based Compensation
ShareBasedCompensation
480000
us-gaap Share Based Compensation
ShareBasedCompensation
237000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
108000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-349000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-497000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
506000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-367000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-490000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-195000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-57000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-50000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6679000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5725000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
158000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
138000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7681000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2503000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2758000
pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
343000
pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
388000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
552000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
11000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9749000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1079000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4020000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12458000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11379000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16429000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11353000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16403000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11379000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16429000
us-gaap Interest Paid Net
InterestPaidNet
2000
us-gaap Interest Paid Net
InterestPaidNet
3000
pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
68000
pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
10000
pali Fair Value Of Warrants Issued To Solicitation Agent
FairValueOfWarrantsIssuedToSolicitationAgent
94000
pali Fair Value Of Warrants Issued To Solicitation Agent
FairValueOfWarrantsIssuedToSolicitationAgent
0
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
249000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
328000
pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
37000
pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
0
pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Other Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
346000
pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Other Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
461000
pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
1975000
pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.045
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129100000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11400000
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2024Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
15
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2024Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
75000
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
112000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span>
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4080000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4080000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3393000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3393000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7607000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7607000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5733000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5733000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1228453
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1228453
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
427862
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
427862
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1000367
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1000367
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
357572
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
357572
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.32
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.32
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.93
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.03
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1291715
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
319541
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
574000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
428000
CY2024Q2 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
128000
CY2023Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
148000
CY2024Q2 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
136000
CY2023Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
138000
CY2024Q2 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
41000
CY2023Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
64000
CY2024Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
75000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
112000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
959000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
375000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
478000
CY2024Q2 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2023Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
387000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q2 pali Accrued Accounts Payable
AccruedAccountsPayable
51000
CY2023Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
166000
CY2024Q2 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
10000
CY2023Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
20000
CY2024Q2 pali Accrued Director Stipends
AccruedDirectorStipends
52000
CY2023Q4 pali Accrued Director Stipends
AccruedDirectorStipends
106000
CY2024Q2 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
131000
CY2024Q2 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
1083000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
98000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
149000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
143000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1555000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
60000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q2 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
5000
pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
5000
CY2023Q2 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1775792
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
272211
CY2023Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
272211
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
144.78
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y1M13D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1731767
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
5.13
pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P6Y6M
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
228162
pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
10.97
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
24
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
53474.38
CY2024Q2 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1775792
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
20.21
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P6Y2M23D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
144000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
471000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
237000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M18D
CY2024Q2 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
1100000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
100000
pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000
us-gaap Royalty Expense
RoyaltyExpense
6750000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
CY2024Q2 pali Class Of Warrant Or Right Number Of Rights Issued
ClassOfWarrantOrRightNumberOfRightsIssued
1
pali Contingent Value Right Pro Rata Net Proceeds From Sale Or Licensing
ContingentValueRightProRataNetProceedsFromSaleOrLicensing
0.80
us-gaap Royalty Expense
RoyaltyExpense
4500000
pali Maximum Aggregate Consideration
MaximumAggregateConsideration
5000000
pali Milestone Payments
MilestonePayments
1500000
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
pali Proceeds Deposited Into The Cvr Escrow
ProceedsDepositedIntoTheCvrEscrow
0.20
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
CY2022Q4 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
69000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
163000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
154000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
35000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
5000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
131000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
180000
CY2024Q2 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
-3000
CY2023Q2 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
-3000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
32000
CY2023Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
5000
us-gaap Payments For Restructuring
PaymentsForRestructuring
128000
us-gaap Payments For Restructuring
PaymentsForRestructuring
180000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
0

Files In Submission

Name View Source Status
0000950170-24-095432-index-headers.html Edgar Link pending
0000950170-24-095432-index.html Edgar Link pending
0000950170-24-095432.txt Edgar Link pending
0000950170-24-095432-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20240630.htm Edgar Link pending
pali-20240630.xsd Edgar Link pending
pali-ex10_48.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pali-20240630_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending